Zavante Therapeutics Inc. recently announced that multiple in vitro studies provide support for Zolyd, combined with certain other antibiotics, as a bacteria killer.
“Zolyd exhibited even greater bacterial killing when used in combination with a number of frequently used antibiotics, which indicates it may play a role as both a first-line agent or in combination with other antibiotics to augment patient care in the hospital setting,” Dr. Cornelius (Neil) Clancy, associate professor of medicine at the University of Pittsburgh, said.
Zavante presented the research and data at the ASM Microbe 2017 Meeting. The company and its research collaborators presented 10 posters related to Zolyd at the event. Zolyd is an investigational, injectable epoxide antibiotic use for fighting bacterial MDR strains that could harm the public.
“Combining antibiotics is frequently employed and offers a comprehensive approach to treating patients who may have deep-seated infections caused by multi-drug resistance bacteria,” Dr. Evelyn Ellis-Grosse, chief scientific officer of Zavante Therapeutics, said. "We are pleased to consistently see these results of Zolyd's synergy and in many cases, restoration of susceptibility to several of our older and commonly used antibiotics."